BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim JY, Chang J. In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus. Yonsei Med J 2016;57:809-16. [PMID: 27189271 DOI: 10.3349/ymj.2016.57.4.809] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Kim MJ, Shim DH, Cha HR, Moon KY, Yang CM, Hwang SJ, Kim KW, Park JH, Lee CG, Elias JA, Sohn MH, Lee JM. Chitinase 3-like 1 protein plays a critical role in respiratory syncytial virus-induced airway inflammation. Allergy 2019;74:685-97. [PMID: 30402955 DOI: 10.1111/all.13661] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
2 Nguyen VH, Dubot-Pérès A, Russell FM, Dance DAB, Vilivong K, Phommachan S, Syladeth C, Lai J, Lim R, Morpeth M, Mayxay M, Newton PN, Richet H, De Lamballerie X. Acute respiratory infections in hospitalized children in Vientiane, Lao PDR - the importance of Respiratory Syncytial Virus. Sci Rep 2017;7:9318. [PMID: 28839157 DOI: 10.1038/s41598-017-09006-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
3 Oh DS, Park JH, Jung HE, Kim HJ, Lee HK. Autophagic protein ATG5 controls antiviral immunity via glycolytic reprogramming of dendritic cells against respiratory syncytial virus infection. Autophagy 2021;17:2111-27. [PMID: 32816604 DOI: 10.1080/15548627.2020.1812218] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Huang Z, Liu X, Wu X, Chen M, Yu W. MiR-146a alleviates lung injury caused by RSV infection in young rats by targeting TRAF-6 and regulating JNK/ERKMAPK signaling pathways. Sci Rep 2022;12:3481. [PMID: 35241728 DOI: 10.1038/s41598-022-07346-6] [Reference Citation Analysis]
5 Kuhdari P, Brosio F, Malaventura C, Stefanati A, Orsi A, Icardi G, Gabutti G. Human respiratory syncytial virus and hospitalization in young children in Italy. Ital J Pediatr 2018;44:50. [PMID: 29728106 DOI: 10.1186/s13052-018-0492-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ruiz SI, Zumbrun EE, Nalca A. Animal Models of Human Viral Diseases. Animal Models for the Study of Human Disease. Elsevier; 2017. pp. 853-901. [DOI: 10.1016/b978-0-12-809468-6.00033-4] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Khan IU, Huang J, Li X, Xie J, Zhu N. Nasal immunization with RSV F and G protein fragments conjugated to an M cell-targeting ligand induces an enhanced immune response and protection against RSV infection. Antiviral Res 2018;159:95-103. [PMID: 30290196 DOI: 10.1016/j.antiviral.2018.10.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
8 Khan IU, Ahmad F, Zhang S, Lu P, Wang J, Xie J, Zhu N. Respiratory syncytial virus F and G protein core fragments fused to HBsAg-binding protein (SBP) induce a Th1-dominant immune response without vaccine-enhanced disease. International Immunology 2019;31:199-209. [DOI: 10.1093/intimm/dxy078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Samy N, Reichhardt D, Schmidt D, Chen LM, Silbernagl G, Vidojkovic S, Meyer TP, Jordan E, Adams T, Weidenthaler H, Stroukova D, De Carli S, Chaplin P. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial. Vaccine 2020;38:2608-19. [PMID: 32057576 DOI: 10.1016/j.vaccine.2020.01.055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]